Novo Nordisk CEO Mike Doustdar discusses the company’s updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk’s oral GLP-1 treatment Wegovy, which has reached over 170,000 patients within four weeks of launch. (Source: Bloomberg)
www.bloomberg.com
#Novo #Nordisk #CEO #Forecast #GLP1 #Pricing
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
